Drug intelligence / Profile preview

SSSC-33

Development stage: Preclinical
Modality: Covalent Small Molecules → Small Molecules
Administration: Oral

Overview

SSSC-33 is a novel Schiff base analogue of 2-aminobenzothiazole, identified for its potential in treating hepatocellular carcinoma. It has demonstrated significant antioxidant potential and the ability to reverse changes in cancerous liver in a diethylnitrosamine-induced rat model. In silico studies suggest favorable pharmacokinetic properties, including potential for oral activity, and molecular docking indicated interactions with checkpoint kinase 1 and vascular endothelial growth factor receptor 2.

Other names: SSSC-33-((benzo[d]thiazol-2-ylimino) methyl)phenol)

Beyond the preview

Go deeper on SSSC-33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSSC-33.

Explore the full profile